IRIS
LEONETTI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.478
AS - Asia 2.104
EU - Europa 1.713
SA - Sud America 385
AF - Africa 130
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 6.816
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.425
SG - Singapore 1.010
IT - Italia 523
CN - Cina 461
BR - Brasile 309
IE - Irlanda 264
SE - Svezia 243
HK - Hong Kong 210
VN - Vietnam 166
DE - Germania 165
NL - Olanda 103
ZA - Sudafrica 84
GB - Regno Unito 67
IN - India 66
RU - Federazione Russa 66
FR - Francia 63
FI - Finlandia 54
AT - Austria 41
AR - Argentina 35
CA - Canada 30
ID - Indonesia 30
BD - Bangladesh 27
KR - Corea 20
IQ - Iraq 19
CI - Costa d'Avorio 18
IR - Iran 18
TR - Turchia 18
CZ - Repubblica Ceca 17
PL - Polonia 16
BE - Belgio 15
ES - Italia 14
JP - Giappone 14
MX - Messico 14
PK - Pakistan 11
UA - Ucraina 11
CO - Colombia 10
LT - Lituania 10
CL - Cile 9
EC - Ecuador 9
MA - Marocco 9
UZ - Uzbekistan 8
BG - Bulgaria 7
TN - Tunisia 7
CH - Svizzera 6
LU - Lussemburgo 6
SA - Arabia Saudita 6
DO - Repubblica Dominicana 5
EG - Egitto 5
PE - Perù 4
PY - Paraguay 4
VE - Venezuela 4
AU - Australia 3
BY - Bielorussia 3
MD - Moldavia 3
NO - Norvegia 3
TH - Thailandia 3
AZ - Azerbaigian 2
DK - Danimarca 2
HR - Croazia 2
KZ - Kazakistan 2
MY - Malesia 2
OM - Oman 2
PH - Filippine 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BS - Bahamas 1
BW - Botswana 1
CR - Costa Rica 1
EE - Estonia 1
GA - Gabon 1
GR - Grecia 1
GY - Guiana 1
HU - Ungheria 1
JM - Giamaica 1
JO - Giordania 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LV - Lettonia 1
MK - Macedonia 1
NG - Nigeria 1
NP - Nepal 1
PR - Porto Rico 1
QA - Qatar 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
TG - Togo 1
TO - Tonga 1
ZM - Zambia 1
Totale 6.816
Salva come PNG Salva come JPEG
Città #
Singapore 547
Ashburn 421
Dallas 415
Chandler 284
Dublin 260
Hong Kong 206
Santa Clara 177
Parma 123
Beijing 107
New York 98
Boardman 94
Shanghai 85
Munich 84
Los Angeles 83
Johannesburg 79
Hefei 63
Ho Chi Minh City 59
Milan 59
Bologna 50
Hanoi 39
Princeton 38
São Paulo 33
Chicago 32
Vienna 31
Helsinki 26
Jakarta 26
Moscow 25
Ann Arbor 24
Marseille 24
Buffalo 23
Nuremberg 23
Turku 23
Verona 22
The Dalles 21
Columbus 20
Frankfurt am Main 20
Rome 20
Des Moines 19
Abidjan 18
London 18
Seoul 18
Amsterdam 16
Bremen 16
Chennai 13
Denver 13
Reggio Emilia 13
Tokyo 13
Warsaw 13
Atlanta 12
Rio de Janeiro 12
West Jordan 12
Modena 11
Pune 11
Toronto 11
Belo Horizonte 10
Bengaluru 10
Biên Hòa 10
Brno 10
Florence 10
Fremont 10
Redondo Beach 10
Brooklyn 9
Brussels 9
Chongqing 9
Haiphong 9
Istanbul 9
Manchester 9
Montreal 9
Poplar 9
Sorbolo 9
Tehran 9
Trento 9
Wilmington 9
Brasília 8
Düsseldorf 8
Tashkent 8
Council Bluffs 7
Houston 7
Seattle 7
Stockholm 7
Tianjin 7
Campinas 6
Curitiba 6
Louvain-la-Neuve 6
North Bergen 6
Phoenix 6
Bolzano 5
Brescia 5
Cairo 5
Cavriago 5
Charlotte 5
Erbil 5
Guayaquil 5
Kyiv 5
Lahore 5
Malo 5
Manaus 5
Olomouc 5
Orem 5
Sofia 5
Totale 4.340
Salva come PNG Salva come JPEG
Nome #
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 203
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 175
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 172
227P Sexual dimorphism in immune profile of early and advanced NSCLC 170
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 161
Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib 154
189P The parallel interrogation of tissue and peripheral blood immune features unveils a bidirectional crosstalk with clinical impact on resected NSCLC 145
The role of miRNA-221 and miRNA-126 in patients with benign metastasizing leiomyoma of the lung: an overview with new interesting scenarios 143
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 136
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 136
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 135
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 133
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 130
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 126
2315P Clinical and blood immune-inflammatory profiling to decode different patterns of acquired resistance in immunotherapy treated NSCLC patients 125
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 121
Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer? 112
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 111
A bug in the resistance to EGFR inhibitors: is there a role for Mycoplasma and cytidine deaminase in reducing the activity of osimertinib in lung cancer patients? 110
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 108
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 105
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial 102
1061P Static and dynamic tracking of radiomic and immunophenotypic features predicts the benefit of immune checkpoint inhibitors in advanced NSCLC 101
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 101
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 100
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 99
Modulating Tumor Microenvironment: A Review on STK11 Immune Properties and Predictive vs Prognostic Role for Non-small-cell Lung Cancer Immunotherapy 99
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 96
Relationship Between the Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) and Lung Adenocarcinoma Patterns: New Possible Insights 95
5P Blood immune-inflammatory dynamic unveils distinctive irAE features in ICI treated NSCLC 95
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 92
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 90
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 89
Small cell lung cancer: Novel treatments beyond immunotherapy 87
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 87
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 87
Hype or hope – Can combination therapies with third-generation EGFR-TKIs help overcome acquired resistance and improve outcomes in EGFR-mutant advanced/metastatic NSCLC? 84
Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M? 83
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers 80
Everolimus in the management of metastatic renal cell carcinoma: An evidence-based review of its place in therapy 80
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors 79
Dynamic evaluation of circulating mirna profile in egfr‐ mutated nsclc patients treated with egfr‐tkis 76
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review 76
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review 74
Radiotherapy for the treatment of distant nodes metastases from oligometastatic urothelial cancer: A retrospective case series 73
EP.15B.05 Predictors of 30-Day Mortality after Systemic Therapy in Hospitalized Lung Cancer Patients: A Retrospective Single-Center Observational Study 72
7P STK11 and Galectin-3 tissue expression entails a prognostic signature in immunotherapy treated NSCLC patients 69
Potential ROle of hypovitaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): a prospective observational study. 68
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study 68
Primary Retroperitoneal Cystoadenocarcinoma: A Systematic Review 68
Letter comments on: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression 67
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors 66
Can we optimize the selection of patients with lung cancer suitable for EGFR+MET double inhibition? 66
Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators 65
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC 65
Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) 65
Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy 64
Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review 61
“Finding NEMO” in NRAS-mutant melanoma: a step towards a sequential strategy? 61
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer 60
Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib 60
P57.08 High Performance Radiomic Classifier to Predict the Response to Immunotherapy in Advanced NSCLC 59
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer 57
Prognostic immunoinflammatory and transcriptomic profiles in patients with pleural mesothelioma undergoing immunotherapy 55
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma 55
The role of the microbiome in cancer and therapy efficacy: Focus on lung cancer 54
Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: A systematic review and meta-analysis 54
Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary? 52
Bridging bench to bedside: The evolution and impact of translational research in oncology. The experience of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 51
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature 48
Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results 43
The link between calcitriol and anticancer immunotherapy: Vitamin D as the possible balance between inflammation and autoimmunity in the immune-checkpoint blockade 41
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 29
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 29
Carboplatin, etoposide, atezolizumab, and bevacizumab in the first-line treatment of patients with extensive stage small-cell lung cancer: the GOIRC-01-2019 CeLEBrATE study 26
Response to the Letter re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed 25
Longitudinal blood immune-inflammatory and radiomic profiling to decode different patterns acquired resistance to immunotherapy in patients with NSCLC 24
Benefit With No Target: Long-Term Outcomes of Chemoimmunotherapy in “PD-L1 Negative” NSCLC 18
Alectinib in Early-Stage Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: Current Evidence and Future Challenges 9
Totale 6.933
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.042
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.042
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202152 0 0 0 0 0 8 5 8 10 5 2 14
2021/2022276 9 4 33 19 2 6 77 15 4 0 27 80
2022/20231.046 111 126 43 87 112 112 20 57 305 3 48 22
2023/2024754 37 49 34 26 74 128 85 35 53 56 60 117
2024/20252.010 63 125 155 149 163 184 137 93 212 193 163 373
2025/20262.770 429 387 820 459 615 60 0 0 0 0 0 0
Totale 6.933